These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 9458093)
41. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Manni A; Xu H; Washington S; Aliaga C; Cooper T; Richie JP; Bruggeman R; Prokopczyk B; Calcagnotto A; Trushin N; Mauger D; Verderame MF; El-Bayoumy K Cancer Prev Res (Phila); 2010 Mar; 3(3):322-30. PubMed ID: 20179301 [TBL] [Abstract][Full Text] [Related]
43. Suppression of mammary gland carcinogenesis by post-initiation treatment of rats with tamoxifen or indole-3-carbinol or their combination. Malejka-Giganti D; Parkin DR; Bennett KK; Lu Y; Decker RW; Niehans GA; Bliss RL Eur J Cancer Prev; 2007 Apr; 16(2):130-41. PubMed ID: 17297389 [TBL] [Abstract][Full Text] [Related]
44. Effects of sequential and combined immuno-endocrine therapies using OK-432 (Picibanil) and tamoxifen on the growth of 7,12-dimethylbenz [alpha] anthracene-induced rat mammary carcinoma. Iino Y; Yoshida M; Tago T; Owada S; Sugamata N; Horiuchi R Jpn J Clin Oncol; 1991 Feb; 21(1):35-8. PubMed ID: 1906118 [TBL] [Abstract][Full Text] [Related]
45. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162 [TBL] [Abstract][Full Text] [Related]
46. 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Grubbs CJ; Hill DL; Bland KI; Beenken SW; Lin TH; Eto I; Atigadda VR; Vines KK; Brouillette WJ; Muccio DD Cancer Lett; 2003 Nov; 201(1):17-24. PubMed ID: 14580682 [TBL] [Abstract][Full Text] [Related]
47. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma. Bitonti AJ; Baumann RJ; Bush TL; Cashman EA; Wright CL; Prakash NJ Anticancer Res; 1996; 16(5A):2553-7. PubMed ID: 8917350 [TBL] [Abstract][Full Text] [Related]
48. 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Anzano MA; Smith JM; Uskoković MR; Peer CW; Mullen LT; Letterio JJ; Welsh MC; Shrader MW; Logsdon DL; Driver CL Cancer Res; 1994 Apr; 54(7):1653-6. PubMed ID: 8137276 [TBL] [Abstract][Full Text] [Related]
50. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Weckbecker G; Tolcsvai L; Stolz B; Pollak M; Bruns C Cancer Res; 1994 Dec; 54(24):6334-7. PubMed ID: 7987824 [TBL] [Abstract][Full Text] [Related]
51. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Rigas JR; Dragnev KH Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250 [TBL] [Abstract][Full Text] [Related]
52. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520 [TBL] [Abstract][Full Text] [Related]
53. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Lubet RA; Clapper ML; McCormick DL; Pereira MA; Chang WC; Steele VE; Fischer SM; Juliana MM; Grubbs CJ Oncol Rep; 2012 May; 27(5):1400-6. PubMed ID: 22307264 [TBL] [Abstract][Full Text] [Related]
54. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911 [TBL] [Abstract][Full Text] [Related]
55. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396 [TBL] [Abstract][Full Text] [Related]